Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ACACB | O00763 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24983775 | 0.84 | ITGB3 (0.44) | L3MBTL1ACACBITGB3ITGA2B | |
| SCHEMBL17022240 | 0.83 | ITGB3 (0.50) | LMNAL3MBTL1ACACBALDH1A1ITGB3 | |
| SCHEMBL2723926 | 0.82 | LDHA (0.54) | ACACBALDH1A1CYP2C19 | |
| SCHEMBL13108101 | 0.82 | ACACB (0.51) | ACACBITGB3ITGA2B | |
| SCHEMBL15851334 | 0.80 | ADRB2 (0.37) | LMNAL3MBTL1ACACBADRB2ADRB1 | |
| SCHEMBL15851332 | 0.80 | ADRB2 (0.37) | L3MBTL1ACACBALDH1A1ADRB2ADRB1 | |
| SCHEMBL15851322 | 0.80 | ADRB2 (0.37) | L3MBTL1ACACBALDH1A1ADRB2ADRB1 | |
| SCHEMBL16940459 | 0.80 | ITGB3 (0.51) | ACACBITGB3ITGA2B | |
| SCHEMBL8628683 | 0.79 | ESR1 (0.47) | — | |
| SCHEMBL15697338 | 0.79 | ESR1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550704-B2 | Method for synthesizing radiopharmaceuticals using a cartridge | FUTURECHEM CO., LTD. (KR) | 2017-01-24 | — | — | US | disclosed |
| US-20150232392-A1 | METHOD FOR SYNTHESIZING RADIOPHARMACEUTICALS USING A CARTRIDGE | FUTURECHEM CO., LTD. (KR) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232392-A1 | METHOD FOR SYNTHESIZING RADIOPHARMACEUTICALS USING A CARTRIDGE | ADCYAP1R1, PAICS, SSTR5 | LMNA 3812/4885L3MBTL1 4666/4885ACACB 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.